Zoryve Availability: What Providers and Prescribers Need to Know in 2026

For dermatologists, primary care physicians, nurse practitioners, and physician assistants prescribing Zoryve (roflumilast), the clinical case for this medication is clear: it's a once-daily, steroid-free PDE4 inhibitor with a robust safety profile and meaningful efficacy across plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. The challenge is getting it into your patients' hands.

This guide covers the access landscape for Zoryve in 2026, including what's driving patient difficulties, how to navigate prior authorization efficiently, and what savings programs are available to support your patients.

Current Zoryve Availability Status (2026)

Zoryve is not listed on the FDA's current drug shortage database. Arcutis Biotherapeutics continues to manufacture the cream (0.05%, 0.15%, 0.3%) and foam (0.3%) formulations without reported supply chain disruptions. Patient access challenges are primarily driven by:

Insurance coverage barriers (PA requirements, step therapy, formulary restrictions)

Limited stocking at community retail pharmacies due to high wholesale acquisition cost

Absence of a generic, meaning no price competition and consistently high retail costs

Formulary and Prior Authorization Landscape

Most commercial insurance plans place Zoryve on Tier 3 or specialty tier, requiring prior authorization. Common PA criteria include:

Confirmed diagnosis of plaque psoriasis, atopic dermatitis, or seborrheic dermatitis documented in the medical record

Documentation that the prescriber is a specialist or in consultation with a dermatologist

Evidence of failure, contraindication, or intolerance to prior topical therapy (often topical corticosteroids — with a minimum trial length specified by payer, commonly 4–8 weeks)

For cases where steroid use is clinically inappropriate (face, genitals, intertriginous areas, pediatric patients), document explicitly why topical corticosteroids are contraindicated or suboptimal. Many payers will accept a letter of medical necessity in lieu of step therapy if a compelling clinical argument is made.

AAD 2025 Guideline Support Strengthens PA Arguments

The American Academy of Dermatology's 2025 treatment guidelines strongly recommend Zoryve cream 0.15% for adults with mild to moderate atopic dermatitis. This guideline endorsement provides useful clinical language for prior authorization letters and appeals. Referencing guideline-concordant care strengthens the medical necessity argument when an insurer requests justification.

Routing Patients to the Right Pharmacy

Because most community retail pharmacies don't routinely stock Zoryve, directing patients to the right pharmacy upfront prevents confusion and delays. Consider:

Specialty pharmacies: CVS Specialty, Walgreens Specialty, Accredo, and Optum Specialty typically carry Zoryve and can handle PA processing on behalf of your practice.

Mail-order pharmacies: Many insurance plans prefer mail order for maintenance dermatology medications. 90-day supplies can lower patient out-of-pocket costs.

ZORYVE Direct program: Arcutis's hub program provides prescription tracking, refill reminders, and connects patients with the right pharmacy channel.

38,004+ patients found their medications in stock

38K+

Find Zoryve In Stock Today →

Patient Savings Programs: What to Tell Your Patients

Arcutis Biotherapeutics offers two patient access programs that your team should be aware of:

ZORYVE Direct Savings Card: For commercially insured patients. Eligible patients may pay as little as $0 per fill. Not valid for Medicare or Medicaid beneficiaries. Patients can enroll at zoryve.com or text SAVE to 440-496-7983.

Arcutis Cares Patient Assistance Program (PAP): Provides Zoryve at no cost for financially eligible patients who are uninsured or underinsured. Enrollment is good for up to 12 months. Apply at arcutiscares.com or call 855-600-3755.

Clinical Profile Recap: Why Zoryve Matters in 2026

As a prescriber, Zoryve's clinical profile offers several advantages worth communicating to your patients and supporting with your PA submissions:

No skin thinning or atrophy — safe for indefinite use, including on the face, neck, genitals, and skin folds

~40% IGA success at Week 8 for plaque psoriasis (cream 0.3%), with itch relief beginning within 24 hours

77% IGA success at Week 8 for seborrheic dermatitis (foam 0.3%)

Well-tolerated — no contact dermatitis or folliculitis seen in clinical trials (unlike Vtama)

Approved down to age 2 for plaque psoriasis (cream 0.3%) and age 2-5 for atopic dermatitis (cream 0.05%)

Skip the calls, skip the stress.

Find Zoryve In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Tools to Help Your Patients Find Zoryve

When patients can't find Zoryve at their pharmacy, they often give up and go without treatment — or stop asking you. Pointing them to a service like medfinder.com/providers can help. medfinder calls pharmacies near your patient's location to find which ones can fill their Zoryve prescription, and texts them the results. This reduces abandonment and keeps your patients on their prescribed therapy. For a practical guide on helping your patients navigate access, see our provider guide to helping patients find Zoryve in stock.